# US 2014/0350234 A1 · Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0350234 A1
- Document ID: US20140350234A1
- Status: Published application
- Kind: A1
- Application number: 14/185,907
- Filed: 2014-02-20
- Published: 2014-11-27
- Earliest claimed: 2004-12-20
- Assignees: ChemGenes Corporation
- Applicants: ChemGenes Corporation
- Inventors: Satya P. Bajpai; Sant K. Srivastav; Suresh C. Srivastava
- Web page: https://patentgrep.com/patent/US20140350234A1

## CPC

- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H 19/06: Pyrimidine radicals
- C07H 19/16: Purine radicals
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present invention is directed to n-alkylated synthetic nucleosides of high regiospecific purity and oligonucleotides that can be utilized for studies on reversal of cytotoxic and mutagenic DNA damage, and as diagnostic tools.

## Claims

### Claim 1

A nucleoside of the formula (II),
wherein,
R1 is methyl;
X is hydrogen, a lower alkyl containing 1 to 6 carbon atoms, or a branched chain lower alkyl;
Y is monomethoxytrityl, dimethyoxytrityl, trimethoxytrityl, or tetrahydropyranyl;
R′ is a phosphoramidite, said phosphoramidite is
P—N(R2,R3)(OCH2CH2CN) or P—N(R2,R3)(OR4),
wherein R2 and R3 are selected from the group consisting of diisopropyl, diethyl, dimethyl, morpholino, and pyrrolidino; and R4 is a lower alkyl containing 1-6 carbon atoms; and
Z is hydrogen, fluoro, or protected amino.

### Claim 2

A nucleoside of the formula (IV),
wherein,
R1 is benzoyl, acetyl, phenoxyacetyl, substituted phenoxyacetyl, isobutyryl, or 9-fluorenylmethoxycarbonyl (9-FMOC);
X is hydrogen, a lower alkyl containing 1 to 6 carbon atoms, or a branched chain lower alkyl;
X1 is methyl;
X2 is a hydrogen atom, a lower alkyl containing 1 to 6 carbon atoms, or a branched chain lower alkyl;
Y is monomethoxytrityl, dimethyoxytrityl, trimethoxytrityl, or tetrahydropyranyl;
R′ is a phosphoramidite, said phosphoramidite is
P—N(R2, R3)(OCH2CH2CN) or P—N(R2, R3)(OR4),
wherein R2 and R3 are selected from the group consisting of diisopropyl, diethyl, dimethyl, morpholino, and pyrrolidino; and R4 is a lower alkyl containing 1-6 carbon atoms; and
Z is hydrogen, fluoro, or protected amino.

### Claim 3

A nucleoside of the formula (VIII),
wherein,
R1 is methyl;
Y is monomethoxytrityl, dimethyoxytrityl, trimethoxytrityl, or tetrahydropyranyl;
R′ is a phosphoramidite, said phosphoramidite is
P—N(R2, R3)(OCH2CH2CN) or P—N(R2, R3)(OR4),
wherein R2 and R3 are selected from the group consisting of diisopropyl, diethyl, dimethyl, morpholino, and pyrrolidino; and R4 is a lower alkyl containing 1-6 carbon atoms;
Z is hydrogen, fluoro, or protected amino; and
R5 is phenoxy acetyl, para or ortho chloro phenoxy acetyl, para or ortho nitro phenoxy acetyl, para or ortho bromo phenoxy acetyl, pivaloyl, 9-fluorenylmethoxycarbonyl (9-FMOC), or a dialkylformamidine.

### Claim 4 (depends on 1, 2, 3)

A method of synthesizing a defined sequence of an oligo-2′-deoxyribonucleotide, comprising the step of:
reacting the nucleoside phosphoramidite of one of claims 1-3 with an oligo-2′-deoxynucleotide to produce said defined sequence of oligo-2′-deoxyribonucleotide.

### Claim 5 (depends on 4)

The defined sequence of oligo-2′-deoxyribonucleotide of claim 4, wherein the nucleoside exhibits at least 95% regiospecific purity.

### Claim 6 (depends on 4)

An in vitro diagnostic agent for reversal of cytotoxic and mutagenic damage to DNA, comprising:
said defined sequence of claim 4, wherein the nucleoside phosphoramidite exhibits at least 95% regiospecific purity.

### Claim 7 (depends on 4)

An in vivo diagnostic agent for reversal of cytotoxic and mutagenic damage to DNA, comprising:
said defined sequence of claim 4, wherein the nucleoside phosphoramidite exhibits at least 95% regiospecific purity.

### Claim 8

A process for preparing N3 alkyl-deoxycytidine, said process comprising the steps of:
reacting N-4-benzoyl-5′-dimethoxytrityl-2′-deoxycytidine with an alkyl iodide to produce N-3 alkyl N-4-benzoyl-5′-dimethoxytrityl-2′-deoxycytidine; and
converting N-3 alkyl N-4-benzoyl-5′-dimethoxytrityl-2′-deoxycytidine into the corresponding phosphoramidite.

### Claim 9 (depends on 8)

The process of claim 8, further comprising the step of:
removing protecting groups N-4-benzoyl and 5′-dimethoxytrityl from N-3 alkyl N-4-benzoyl-5′-dimethoxytrityl-2′-deoxycytidine to produce N-3-alkyl-2′-deoxycytidine.

### Claim 10 (depends on 1, 2, 3)

An oligo-2′-deoxyribonucleotide, comprising at least one of the nucleoside of claims 1-3.
